STAT July 10, 2024
Elaine Chen

The Food and Drug Administration rejected Novo Nordisk’s weekly insulin for the treatment of diabetes in a rare setback for the pharmaceutical giant.

The agency has requests related to the manufacturing process and the use of the insulin specifically in type 1 diabetes patients, Novo said in a statement Wednesday. The company, which had submitted an application for the drug for...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
First Comprehensive Review of SMA Drugs Offers Long-Term Insights, Outcome Gaps
Health Rounds: Next Generation Lilly Weight-loss Drug Shows Added Heart, Liver Benefits
Drugmaker might be 1st healthcare company to top $1 trillion valuation
Pharma Pulse 9/5/24: Legal Advice for DSCSA Compliance Teams, Pharmacy Students Discuss Learning Through Social Media Platforms & more
RNA treatment shows promise for enhancing memory and reducing anxiety

Share This Article